Zarxio, a Cheaper Alternative to Neupogen


The FDA just approved zarxio, a biosimilar to neupogen:


It is expected to be much cheaper than neupogen. Usually though, oncologists tend to prescribe neulasta which is a version of neupogen that stays longer in the body. So the nest question is whether zarxio's manufacturer has a similar version of zarxio to offer...